Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

E3XBio

E3XBio
2013 FOUNDED
PRIVATE STATUS
Grant LATEST DEAL TYPE
1 INVESTORS
Description

Developers of inhibitors and activators of E3 Ubiquitin ligases intended to be used for drug discovery and development. The company's platform offers streamlined screening paradigm and direct cellular and animal model assays, enabling healthcare institutions to avail a simplified, pragmatic drug discovery approach to identify first-in-class small molecules specifically directed towards Ub E3 HECT ligases.

Website
Ownership Status
Privately Held (no backing)
Financing Status
Corporation
Primary Industry
Drug Discovery
Primary Office
  • San Francisco, CA
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore E3XBio’s full profile, request a free trial.

E3XBio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Grant 10-Feb-2014 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

E3XBio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Breakout Labs Not-For-Profit Venture Capital Minority 000 0000 000000 0

E3XBio Executive Team (4)

Name Title Board
Seat
Contact
Info
Lori Rafield Ph.D Co-Founder & Chief Executive Officer
Paul Godowski Ph.D Co-Founder & Chief Scientific Officer
David Morgans Ph.D Co-Founder & Vice President, Drug Discovery
William Harte Ph.D Co-Founder & Vice President, Technology Platforms